<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingJeffrey A. Engelman, Pasi A. Jänne, Kreshnik Zejnullahu et al.|Science|2007Cited by 4.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung CancerBenjamin Solomon, Fiona Blackhall, Tony Mok et al.|New England Journal of Medicine|2014Cited by 3.2k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Federico Cappuzzo, Michael McCleod et al.|The Lancet Oncology|2019Cited by 1.7k
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerFederico Cappuzzo, Marileila Varella‐Garcia|JNCI Journal of the National Cancer Institute|2005Cited by 1.6k
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony Mok, Makoto Nishio et al.|The Lancet Respiratory Medicine|2019Cited by 937